Search

Displaying results 4901 - 4910 of 8010 in total
  1. Drug

    Metiamide

    go.drugbank.com/drugs/DB08805
    Experimental

    Metiamide is an H-2 receptor antagonist derived from burimamide. It was an intermediate product on the path to developing cimetidine.

  2. Drug

    Vicriviroc

    go.drugbank.com/drugs/DB06652
    Investigational

    Vicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1. … This drug was developed by Schering-Plough.

  3. Drug

    Reglitazar

    go.drugbank.com/drugs/DB04971
    Experimental

    Reglitazar, an isoxazolidine-3,5-dione derivative, is being developed by Pfizer for the treatment of diabetes. It is the first non-thiazolidenedione to enter clinical trials.

  4. Drug

    GTI-2501

    go.drugbank.com/drugs/DB05406
    Experimental

    The drug is in a phase II clinical trial in combination with docetaxel for the treatment of hormone refractory prostate cancer.

  5. Drug

    N-acetylsulfanilyl chloride

    go.drugbank.com/drugs/DB12337
    Investigational

    ASC has been investigated for the screening of Patients Undergoing Screening or Surveillance Colonoscopy.

  6. Drug

    Leptazoline D

    go.drugbank.com/drugs/DB15554
    Experimental

    Leptazoline D is a polar oxazoline from the Cyanobacterium Leptolyngbya sp. Also see [Leptazoline A], [Leptazoline B], and [Leptazoline C].

  7. Drug

    Streptolydigin

    go.drugbank.com/drugs/DB04785
    Experimental

    Streptolydigin is an antibiotic isolated from culture filtrates of Streptomyces lydicus. It is active against gram-postive bacteria except micrococci.

  8. Drug

    LP-2307

    go.drugbank.com/drugs/DB17470
    Experimental

    LP-2307 is an investigational allogeneic large multivalent immunogen (LMI) vaccine developed by Avanir. It was investigated for melanoma.

  9. Drug

    iCo-007

    go.drugbank.com/drugs/DB05268
    Investigational

    iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis

  10. Drug

    Ponazuril

    go.drugbank.com/drugs/DB11452
    ExperimentalVet approved

    Ponazuril, sold by the Bayer Corporation under the trade name Marquis, is a drug currently approved for the treatment of equine protozoal myeloencephalitis in horses, caused by Sarcocystis neurona.